No doubt, Aphria is gaining momentum as part of the general rally in cannabis stocks. Fueled by the massive $5 billion investment in Canopy Growth, cannabis stocks have been surging in the past month. The rally was revitalized recently after Aurora Cannabis announced a $290 million investment in a Vancouver-based company that has a huge foothold in the South American cannabis market.
Given the massive coverage of these deals, it’s not surprising that we’d see Canopy and Aurora shares soar. And yet Aphria has risen even more than either of those companies. Whereas Canopy gained 106% from August 14 to September 11 — a big gain its own right — Aphria rose nearly 150%, which is strange, because there hasn’t been any big acquisition news from Aphria.
So, what explains the fact Aphria has done far better than Canopy or Aurora over the past month?
One major factor behind the rally is the fact that cannabis is about to be legalized on October 17. This news has driven a flurry of coverage of the sector, which may have played a role in the late-summer rally. No doubt, legalization is good news for Aphria. And yet this development will not affect Aphria any more than it does Canopy or Aurora. So, why is Aphria the big winner in the late-summer cannabis surge?
One fact that may have investors eyeing Aphria is its earnings. Unlike Canopy and Aurora, Aphria has turned a positive bottom-line profit in several recent quarters. In fact, it has had a positive net income for three of the past four fiscal years. Net income has been a consistent blot on the otherwise prosperous cannabis industry, with both Canopy and Aurora failing to deliver positive earnings in recent fiscal years. So, while Canopy and Aurora may have been the drivers of the cannabis rally, Aphria’s fiscal soundness may have made it the main beneficiary.
A final possibility is that M&A speculation regarding Aphria may have fueled investor interest in the company. Since the Canopy acquisition, there has been a flurry of speculation that Aphria or Aurora might be the target of the next big M&A transaction. Since Aphria is the smaller of the two, it seems the more likely (i.e., more attainable) candidate.
This is significant because Canopy’s post-deal rally may have peaked. Within a week of the Canopy acquisition announcement, the stock had already reached the level that Constellation Brands paid for it. Since then, it has shot up well beyond that level. This may have sent investors looking for other options where potential buyouts were ahead of them rather than behind them. M&A transactions like Constellation’s Canopy acquisition tend to drive share prices up, as investors take the purchase as a vote of confidence in the target company. It’s possible that investors see Aphria as the next big M&A target, since it’s small enough to be acquired and profitable enough to be worth acquiring.
When you buy heavily cyclical stocks at low prices… and then hold the shares until the cycle reaches its peak… you can make a very healthy profit.
Every investor knows that. But many struggle to identify the best opportunities.
Except The Motley Fool may have a plan to solve that problem! Our in-house analyst team has poured thousands of hours into their proprietary research – and this is the result.
Our top advisor Iain Butler has just identified his #1 stock to buy in 2018 (and beyond).
The last time this stock went from the low point of its cycle to the peak… shares shot from $12 to $40 inside of 4 years. That’s an 300%-plus return. And if you missed out on that ride, today might just be your second chance.
Fool contributor Andrew Button has no position in any of the stocks mentioned.